Indications for: BETAGAN
Open-angle glaucoma. Ocular hypertension.
1–2 drops of 0.5% 1–2 times daily. Remove contact lenses prior to administration; may reinsert 15mins later.
Bronchial asthma. Severe COPD. Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt cardiac failure. Cardiogenic shock.
Mild or moderate COPD, bronchospastic disease; not recommended. Impair compensatory tachycardia. Increase risk of hypotension. Diabetes. Hyperthyroidism. Choroidal detachment after filtration procedures. Diminished pulmonary function. Cerebrovascular insufficiency. Angle-closure glaucoma. Myasthenia. Withdraw gradually before surgery. Discontinue at first sign of cardiac failure. Vascular insufficiency (eg, Raynaud's phenomenon). Sulfite sensitivity. Pregnancy. Nursing mothers.
Additive effects with systemic β-blockers, digitalis, calcium blockers, reserpine, phenothiazine-related drugs. Mydriasis with epinephrine.
Transient ocular burning, stinging, blepharoconjunctivitis, bradycardia, hypotension, iridocyclitis, headache, transient ataxia, dizziness, lethargy, urticaria, pruritus, decreased corneal sensitivity; systemic absorption (bronchospasm, cardiac failure).
Half-life: 20 hours.
Generic Drug Availability:
Soln—5mL, 10mL, 15mL